Date
30 June – 1 July 2022
Place
online
Language
English
Goals of the module
Participants
- have an overview on sex differences in oncology and the scientific, clinical and societal implications of sex differences for prevention, diagnosis and treatment of cancer.
- are familiar with the combined impact of sexual hormones and sex chromosomes on cancer susceptibility with a focus on intrinsic control of cancer initiating cell populations, tumor microenvironment and systemic determinants of cancer development.
Content of the module
- Rationale for considering sex and gender in cancer prevention and treatment
-
-
- Sex differences in epidemiology of various cancers
- Sex and gender differences in carcinogen exposition (UV light, smoking, environmental carcinogens)
-
-
- Sex chromosomes and their impact on cancer susceptibility
-
- Estrogens and their impact on cancer risk in females and males
- Endocrine disruptors
- Androgens and their impact on cancer risk in females and males
-
- Impact of sex on systemic determinants of cancer development
- immunity
- tumor microenvironment
- cancer initiating cells
- metabolism
- microbiome
-
- Clinical implications of sex and gender differences in cancer
- Sex differences in response and toxicity of anticancer therapies (cytotoxics, targeted therapies and immunotherapies)
- Sex differences in oncological surgery and radiotherapy outcomes
- Implications for clinical trial design and reporting of results
- Sex-specific drug dosing strategies?
- Sex-specific cancer prevention efforts?
- Clinical implications of sex and gender differences in cancer
Lecturers
The oncology module was conceived and organised by our International Cancer Prevention Institute (ICPI).
Dr. med. Berna Özdemir, Universitätsklinik für Medizinische Onkologie, Inselspital, Universitätsspital Bern (Chair)
Dr. David Combarel, Institut de Cancérologie Gustave Roussy, Paris
Prof. Dr. Paolo Dotto, Department of Biochemistry, University of Lausanne/ International Cancer Prevention Institute
Prof. Jacques Fellay, Precision Medicine Unit, Lausanne University Hospital (CHUV), University of Lausanne; School of Life Sciences, École Polytechnique Fédérale de Lausanne; Swiss Institute of Bioinformatics, Lausanne
Prof. Ramaswamy Govindan, Medical Oncology, Washington University School of Medicine in St. Louis, St. Louis
Dr. Rob Verhoefen, Cancer Center Amsterdam, Amsterdam University Medical Centers
PD Dr. med. Dorothea Wagner, Department of Oncology, Lausanne University Hospital and University of Lausanne
Registration Deadline
1 June 2022